Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Dr Michael Mosley's son is picking up his dad's weight loss campaign with the publication of a new book. Michael Mosley was a ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the ...

It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...